MiroBio is a clinical-stage company focused on developing treatments to “restore the immune balance” in autoimmune patients, which occurs when a person’s immune system attacks their own body’s tissues. Led by Professor Simon Davis and Professor Richard Cornall, the company exited the University of Oxford in 2019, and raised $130 million in venture funding, including a $97 million tranche in June from a group of backers including Oxford Science Enterprises .OSE), an investment firm that has backed more than 100 Oxford University spinouts since its inception in 2015.
Oxford University and nearby Cambridge University have long been the centers of gravity for both VC and M&A activities. Back in 2014, Google spun off AI-focused Cambridge spinout DeepMind, which acquired two AI-focused teams from Oxford later that year.
Recently, another Oxford University spinout called Deeperson $7.3 million deal back in November.
Initially founded as Oligogen in 1987, Gilead develops antiviral drugs used in the treatment of hepatitis B, HIV/AIDS, influenza, and more recently – COVID-19. company this week Raise your sales forecast That’s on the back of anticipated demand for its COVID-19 drug Vaclari, which was given FDA approval earlier this year.
By taking MiroBio in-house, it will serve Gilead with MiroBio’s proprietary technology and “portfolio of immune inhibitory receptor agonists.” for a statement,